• STAT+: Cytokinetics drug improves blood flow in patients with inherited form of heart disease

    16 days ago - By STAT

    Cytokinetics said Monday that its experimental drug demonstrated statistically significant improvements in blood flow for patients with an inherited form of heart disease - a result that compares favorably to a competing heart drug recently acquired by Bristol Myers Squibb.
    In a small, mid-stage clinical trial, 13 of 14 patients, or 93%, treated with a higher dose of the Cytokinetics drug, called CK-274, achieved improvement in blood flow to a target level where they no longer met the threshold for being diagnosed with their disease - obstructive hypertrophic cardiomyopathy, or HCM. No...
    Read more ...